Assay Capabilities

In-house developed analysis pipelines and metrics powering actionable insights.

Normalised Organoid Growth Rate (NOGR)

NOGR is our in-house developed growth rate–based metric designed to improve the accuracy of longitudinal organoid drug response profiling. With intra-well normalization, automated QC, and correction for baseline growth differences across organoid lines, it robustly distinguishes cytostatic from cytotoxic effects across organoid models. By extracting growth directly from brightfield images through Orbits, our proprietary label-free viability and cell death segmentation model, NOGR avoids the confounding effects of fluorescent viability dyes.

Deben C, et al. Commun. Biol., 2024

Response Dynamics

Monitor drug effects over time, not just at a single endpoint. Capture onset, kinetics, and recovery of drug effects with growth-rate dynamics tracked across multiple timepoints.

Example: KRAS G12D mutant pancreatic cancer organoids treated with MRTX1133

Drug Synergy Studies

Our platform identifies synergistic and tumor-selective drug combinations with the added power to separate cytotoxic synergy from cytostatic or merely additive effects. Using HSA, ZIP, Loewe, and Bliss models together with NOGR heatmaps, we generate a more precise and biologically relevant assessment of drug combination activity.

Deben C, et al. J Exp Clin Cancer Res., 2024